-+ 0.00%
-+ 0.00%
-+ 0.00%

Alpha Tau Q1 FY26 net loss more than doubles to $22.9 million

PUBT·05/18/2026 20:02:02
Listen to the news
Alpha Tau Q1 FY26 net loss more than doubles to $22.9 million
  • Alpha Tau Medical posted a Q1 net loss of USD 22.94 million, widening from USD 8.69 million a year earlier.
  • Research and development expense climbed to USD 10.98 million from USD 7.17 million, due to higher clinical trial activity, compensation, raw material purchases, and milestone payments tied to PMDA marketing authorization in Japan.
  • Financial expense swung to USD 9.64 million from financial income of USD 716,000, driven by remeasurement of warrants liability.
  • Cash, cash equivalents, short-term deposits and restricted deposits rose to USD 80.2 million as of March 31 from USD 76.9 million at Dec. 31.
  • Completed enrollment of 88 patients in the U.S. pivotal ReSTART trial in recurrent cutaneous squamous cell carcinoma; reported interim REGAIN glioblastoma data showing 100% local disease control and 67% complete response rate in the first three patients.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alpha Tau Medical Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605181601PRIMZONEFULLFEED9722157) on May 18, 2026, and is solely responsible for the information contained therein.